In Vivo Neuroregeneration
Leading A Revolution in Brain Repair

About Us

NeuExcell is an early stage gene therapy company focusing on neurodegenerative diseases. We have developed a disruptive neural repair technology through astrocyte-to-neuron conversion. Our vision is to improve the quality of life of millions of patients worldwide who are suffering from neurodegenerative conditions by using the power of gene therapy to restore damaged neural tissue.

A Breakthrough in Brain Repair - In Vivo Regeneration

Despite great investment and hope in the past decades, there is no effective therapy that can cure ALS or reverse the progression of Alzheimer's disease. Likewise, therapies that treat stroke or brain/spinal cord injury have limited and variable efficacy at the best. The fundamental problem that has not been adequately addressed is how to recover a sufficient number of lost neurons to restore lost brain functions.

In neurodegenerative or acutely injured brains, neurons die while glial cells, a group of supporting cells surrounding neurons, become reactive and proliferate. Our in vivo transdifferentiation technology takes the advantage of those reactive and proliferative  glial cells and converts them into functional neurons with high efficiency. The newly generated neurons are fully functional and integrate into existing brain circuits, leading to functional recovery. This technology has a broad scope of applications to treat neurodegenerative diseases and neural injuries.

Our Team

Peter Tombros

Executive Board Chair, Acting CEO

Gong Chen, PhD

Founder, Chief Scientific Officer

Xi Qin, MBA

Chief Financial Officer

Ronald HW Lorijn, MD PhD MBA

Executive Board Director

J. David Jacobs, JD

General Counsel, Secretary

Jie Xu

Head of Discovery

Elizabeth White

Chief Business Strategy Officer